Sheffield is one of the two UK Centres treating trophoblastic tumours. The Sheffield Trophoblastic Screening and Treatment Centre covers a population of over 22 million from the North of England and North Wales.
Around 600 women each year are registered in Sheffield following the diagnosis of a molar pregnancy. Therefore, there is a wealth of clinical, biochemical and histopathological date available for research.
As well as the Sheffield GTN team developing research projects we also combine with the other two centres in the UK - Charing Cross Hospital and Ninewells Hospital to develop joint projects.
Every two years the Sheffield Team attends the International Society for the Study of Trophoblastic Disease (ISSTD) conference where research from across the globe is discussed
A recent initiative of which Sheffield is part, is the European Organisation for Treatment of Trophoblastic Disease (EOTTD) formed to develop optimum treatment for GTN patients
In order to extend and focus our research we have defined three main themes - aimed broadly at:
assessing best practice in clinical management.
helping understand the aetiology.
evaluating long-term physical and psychological morbidity.
Recently completed projects:
Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?
Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.
Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia.
A conservative approach in persistent low-level elevation of serum beta-human chorionic gonadotropin following chemotherapy for gestational trophoblastic neoplasia.
Key peer reviewed publications in trophoblastic disease involving the Sheffield TDC team.
Winter M.C., Tidy J., Singh K., Sarwar N., Aguiar X., Seckl M.J. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN)
Winter MC. Treatment of low-risk Gestational Trophoblastic Neoplasia. Best Practice & Research Clinical Obstetrics and Gynaecology 2021. doi: 10.1016/j.bpobgyn.2021.01.006
Ireson J, Jones G, Winter MC, Radley SC, Hancock BW, Tidy JA. Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach. Lancet Oncology, 2018, e56–64. doi: 10.1016/S1470-2045(17)30686-1
Parker VL, Pacey AA, Palmer JE, Tidy JA, Winter MC, Hancock BW
Classification systems in Gestational trophoblastic neoplasia - Sentiment or evidenced based? Cancer Treatment Reviews, 2017 May, 56, pp. 47–57. doi: 10.1016/j.ctrv.2017.04.004
Gillett S, Singh K, Ireson J, Hills A, Winter M, Tidy J, Logan R, Hancock B
Evolution of a teenage and young adult service, in Sheffield, UK, for patients with gestational trophoblastic neoplasia. Journal of Reproductive Medicine, 2016, May-June, 61(5–6), pp. 235–7. Link to review.
Taylor F, Short D, Harvey R, Winter MC, Tidy J, Hancock BW, Savage PM, Sarwar N, Seckl MJ, Coleman RE. Late spontaneous resolution of persistent molar pregnancy. BJOG, 2016 June, 123(7), pp. 1175–81. doi: 10.1111/1471-0528.13867
Winter MC, Tidy JA, Hills A, Ireson J, Gillett S, Singh K, Hancock BW, Coleman RE. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. Gynecologic Oncology, 2016 December, 143(3), pp. 565–570. doi: 10.1016/j.ygyno.2016.10.001
Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane database of systematic reviews, 2016 June 9, (6). doi: 10.1002/14651858.CD007102.pub4
Macdonald MC, Hancock BW, Winter MC, Coleman RE, Tidy JA. A review of the management and outcomes of patients treated for low-risk gestational trophoblastic neoplasia in Sheffield, UK between 1997 and 2006. Journal of Reproductive Medicine, 2016, 61(7-8), pp. 341–346. Link to review.
Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane database of systematic reviews, 2016 Jan 13, (1):CD008891. doi:10.1002/14651858.CD008891.pub2
Price JM, Lo C, Abdi S, Winter MC, Coleman RE, Tidy J, Hancock BW. The Role of Computed Tomography Scanning of the Thorax in the Initial Assessment of Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2015 November, 25(9), pp. 1731–6. doi: 10.1097/IGC.0000000000000534
Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW, Coleman RE, Seckl MJ. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. The Journal of Reproductive Medicine, 2014 January-February, 59(1-2), pp. 7–12. Link to review.